Editorial

Comments on the 2020 ESC guidelines for the management of adult congenital heart disease

Comentarios a la guía ESC 2020 sobre el tratamiento de las cardiopatías congénitas en el adulto

SEC Working Group for the ESC 2020 Guidelines for the Management of Adult Congenital Heart disease, Expert Reviewers for the ESC Guidelines for the Management of Adult Congenital Heart Disease and SEC Guidelines Committee*

INTRODUCTION

The aim of this editorial is to present the most relevant and innovative aspects of the new European Society of Cardiology (ESC) 2020 Guidelines for the Management of Adult Congenital Heart Disease (CHD), in line with the recommendations of the Clinical Practice Guidelines established by the Executive Committee of the Spanish Society of Cardiology.

This new version of the guidelines is an update of the guidelines published in 2010 based on a systematic review of advances made over the past 10 years.

The guidelines use a new format indicating changes made to the previous guidelines (table 1), as well as an extremely useful series of algorithms to understand the recommendations, new sections listing situations with a lack of evidence, and summaries of key messages. The section on specific lesions now includes a segment on coronary anomalies, of considerable interest for cardiologists not specifically focused on CHD. Additionally, the term “grown-up congenital heart disease” has been replaced with “adult congenital heart disease”, which is more appropriate and in keeping with standard practice.

One of the main objectives of clinical practice guidelines is to support recommendations with as much evidence as possible. This specialty covers a broad range of diseases, and the number of patients is often low, with only a few randomized studies or meta-analyses. Only 3 recommendations have a level of evidence B, and 1 has level A (all from previously published guidelines), most of them based on expert consensus and including several controversial recommendations, such as removal of the acute vasodilator test, inclusion of the treat-and-repair strategy or pulmonary vascular resistance (PVR) limits in decision-making for atrial septal defect (ASD) closure, pulmonary vasodilator therapy in Eisenmenger syndrome, and cutoff points for right ventricle (RV) volume for pulmonary valve replacement in tetalogy of Fallot. Moreover, the broad heterogeneity of the adult CHD patient population makes individualization in decision-making inevitable. Nevertheless, these guidelines are a fundamental tool for assessing this population and add essential and highly practical information for management.

GENERAL ASPECTS

Organization of care

The ESC 2020 document emphasizes recommendations for the transition from pediatric to adult care and underscores the need to establish advanced care planning by creating multidisciplinary teams in specialized facilities. It outlines the human resources that should be offered by all specialized units, now featuring, in comparison with prior guidelines, the inclusion of specialist nurses, experts in pulmonary vasculature diseases, geneticists, and a palliative care team.

The previous guidelines stratified the care of patients into 3 levels: patients who need care exclusively in specialized facilities, patients whose care can be shared with general cardiology units, and patients who can be treated in nonspecialized units, with access to specialized care if necessary. The new guidelines maintain these recommendations, assert that the degree of complexity should not be the only criterion for assigning patients to a certain level of care, and advocate that all patients be assessed at least once by a specialized unit that will decide the necessary level of care and follow-up intervals. An updated table categorizes levels of complexity and reclassifies patients with transposition of the great arteries surgically repaired by the arterial switch procedure, now placing them in the moderate complexity category.

Diagnostic work-up

A multimodal approach is necessary for complete patient assessment in a multidisciplinary setting, allowing CHD imaging experts to interact with other specialists (e.g., surgeons, interventional cardiologists, electrophysiologists). Cardiopulmonary stress testing is considered key to objectively defining the patient's clinical status and optimal timing for surgery, mentioning that the test should be part of follow-up protocols and introducing for the first time the usefulness of biomarkers in patients’ clinical progress.
Pregnancy, contraception, and genetic counseling

This section is highly relevant and includes a table classifying conditions with a high or extremely high risk of pregnancy-related complications. The latter group includes patients with pulmonary hypertension or Fontan circulation with clinical complications, in whom formal contraindication of pregnancy is recommended.

HEART FAILURE

Although specific diagnostic criteria are not established, the importance of actively screening high-risk patients is emphasized, as such patients often exhibit atypical symptoms. The section on biomarkers mentions that BNP and NT-ProBNP are less useful for diagnosing heart failure (HF) due to the lack of cutoff points for different cardiac lesions. Serial testing as a prognostic factor is recommended, although the utility of the biomarkers is limited in patients with Fontan surgery. Furthermore, hypoxia is mentioned as a possible inducer of peptide secretion, hence increased peptides in cyanotic patients should be interpreted within the clinical context.

Any significant structural lesion, including arrhythmias, should be treated surgically or percutaneously in all patients who experience a new HF episode. The pathophysiologic heterogeneity of HF in these patients limits the extrapolation of results from pharmacologic studies carried out in patients with acquired heart disease. Standard HF treatment is recommended for all patients with biventricular circulation and left ventricular dysfunction and, for the first time, also for symptomatic patients with systemic RV dysfunction; the guidelines include no recommendations on sacubitril/valsartan or sodium–glucose cotransporter type 2 inhibitors, as there is no evidence in this population. The utility of cardiac resynchronization therapy is mentioned, although its indications are still being researched.

It is recommended that acute HF be treated at experienced centers able to start advanced treatments, such as extracorporeal membrane oxygenation (ECMO) or ventricular assist. Additionally, the guidelines propose that heart transplant candidates be assessed at transplantation hospitals with cardiologists specialized in HF within CHD, one of the most innovative concepts in

Table 1
New and revised recommendations

<table>
<thead>
<tr>
<th>Arrhythmia</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
</tr>
<tr>
<td>N/R</td>
</tr>
<tr>
<td>N</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Eisenmenger syndrome/pulmonary artery hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>R</td>
</tr>
<tr>
<td>R</td>
</tr>
<tr>
<td>N/R</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Shunt lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
</tr>
<tr>
<td>N/R</td>
</tr>
<tr>
<td>N</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Left ventricular outflow tract obstruction and aortopathies</th>
</tr>
</thead>
<tbody>
<tr>
<td>R</td>
</tr>
<tr>
<td>L</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Right ventricular outflow tract obstruction/tetralogy of Fallot/Ebstein</th>
</tr>
</thead>
<tbody>
<tr>
<td>R</td>
</tr>
<tr>
<td>R</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Transposition of the great arteries</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Fontan circulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Coronary artery anomalies</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
</tr>
</tbody>
</table>

AS, aortic stenosis; ASD, atrial septal defect; AV, atrioventricular; ccTGA, congenitally corrected transposition of the great arteries; CMR, cardiovascular magnetic resonance; LVOTO, left ventricular outflow tract obstruction; 6MWT, 6-minute walk test; PAH, pulmonary artery hypertension; PAP, pulmonary artery pressure; PDA, patent ductus arteriosus; PR, pulmonary regurgitation; PVR, pulmonary vascular resistance; RVEDVi, right ventricular end diastolic volume indexed; RVOT, right ventricular outflow tract; RVOT, right ventricular outflow tract obstruction; SV, supraventricular tachycardia; TOF, tetralogy of Fallot; TPVI, transcatheter pulmonary valve implantation; TR, tricuspid regurgitation; VSD, ventricular septal defect; VT, ventricular tachycardia; WU, Wood units.

AS, aortic stenosis; ASD, atrial septal defect; AV, atrioventricular; ccTGA, congenitally corrected transposition of the great arteries; CMR, cardiovascular magnetic resonance; LVOTO, left ventricular outflow tract obstruction; 6MWT, 6-minute walk test; PAH, pulmonary artery hypertension; PAP, pulmonary artery pressure; PDA, patent ductus arteriosus; PR, pulmonary regurgitation; PVR, pulmonary vascular resistance; RVEDVi, right ventricular end diastolic volume indexed; RVOT, right ventricular outflow tract; RVOT, right ventricular outflow tract obstruction; SV, supraventricular tachycardia; TOF, tetralogy of Fallot; TPVI, transcatheter pulmonary valve implantation; TR, tricuspid regurgitation; VSD, ventricular septal defect; VT, ventricular tachycardia; WU, Wood units.

Summary of Table 3 by Baumgartner et al. Reproduced with permission from the European Society of Cardiology and Oxford University Press.
the current version. However, there is no mention that the multidisciplinary team evaluating these patients should also include other specialists with experience in CHD, such as cardiac surgeons, anesthesiologists, intensivists, and hepatologists.

ARRHYTHMIAS

The section on arrhythmias and sudden cardiac death (SCD) has been expanded considerably in this version and highlights the importance of understanding the potential mechanisms involved and the anatomy underlying arrhythmias in these patients. It also includes a table with clear, visual information on the risk of the various types of arrhythmia according to CHD, in particular the potential risk of hemodynamic decline and sudden death in supraventricular arrhythmias with rapid atrioventricular (AV) conduction.

Regarding diagnosis, there is a mention of the questionable role of Holter monitoring in screening for tachyarrhythmias in asymptomatic patients, given the high prevalence of events with no clinical or therapeutic implications, in contrast with its usefulness in screening for sinus node dysfunction and atrioventricular block.

Patients with CHD, particularly those with moderately or severely complex heart disease, should be assessed by multidisciplinary teams in facilities experienced in managing adults with CHD and associated arrhythmias (class I); the importance of maintaining sinus rhythm is emphasized, particularly in more complex heart diseases. In cases of sustained, symptomatic, and recurrent supraventricular tachyarrhythmia, catheter ablation is proposed as a first option over pharmacologic treatment whenever possible. Long-term oral anticoagulant therapy is recommended for atrial fibrillation (AF) or intra-atrial reentrant tachycardia (IART) in patients with moderate or complex CHD, whereas in patients with a simple CHD, the CHA2DS2-VASc score should be used for decision-making. For patients not receiving anticoagulation who have AF or IART > 48 hours, the need for transesophageal echocardiography (TEE) before cardioversion is mentioned, but there are no recommendations for episodes < 48 hours, an issue addressed in the new version of the AF guidelines published at the same time.10 In these cases, the complexity of the heart disease and the patient’s clinical status should be considered when evaluating the need for TEE before cardioversion.

The indication for pacemaker implantation is proposed for patients with bradycardia-tachycardia syndrome to prevent IART (class Ila) when ablation is ineffective and to resynchronize patients with congenitally corrected transposition of the great vessels (systemic RV) who have complete AV block or require pacing > 40%, and His bundle pacing is mentioned as an alternative to conventional resynchronization.

The section on SCD and risk stratification describes, along with known uncertainties, the most commonly accepted indications in CHD for an implantable cardioverter defibrillator (ICD) for either primary or secondary prevention. Subcutaneous ICD is listed as an alternative for patients with anatomic difficulties, provided that they do not require pacing and in view of the limitations of oversensing and lack of antitachycardia pacing.

PULMONARY HYPERTENSION

For the first time, the new definition of precapillary pulmonary hypertension (PH) is included in clinical practice guidelines, reducing the cutoff point for mean pulmonary artery pressure from 25 to 20 mmHg, while the cutoff points of PVRs ≥ 3 WU and pulmonary capillary pressure ≤ 15 mmHg remain unchanged.

Risk assessment is introduced as a guide for treatment, and initial or sequential combination treatment is recommended. In Eisenmenger syndrome, endothelin receptor antagonist therapy is now generally recommended for patients with reduced exercise capacity (defined as distance < 450 m in the walk test), instead of according to functional class. In the absence of response, combined treatment is recommended. If necessary, inhaled or subcutaneous prostacyclin therapy is recommended instead of intravenous epoprostenol, in order to prevent complications associated with a permanent central intravenous catheter.

There are no long-term therapy recommendations for patients with elevated PH and PVRs that contraindicate shunt closure or for patients with segmental PH.

SPECIFIC LESIONS

Shunts

Pretricuspid shunts

Temporary balloon occlusion of the defect is proposed to assess the behavior of the left ventricle (LV) end-diastolic pressure and to evaluate the indication for closure to treat ASD in patients with high LV pressures. Right-heart catheterization and exercise testing are recommended for patients with evidence consistent with PH (systolic pulmonary arterial pressure > 40 mmHg on echocardiography), in order to ascertain PVRs, the quotient between pulmonary and systemic flow (QP/QS), and the presence of exercise-induced systemic desaturation. These aspects are key for indicating shunt closure. PVRs < 5 WU with QP/QS > 1.5 are established as the upper limit of PH in ASD to allow defect closure. Indications for closure (figure 1) are more restrictive than in the 2010 guidelines and definitively contraindicate closure in the case of PVRs > 5 WU after pulmonary vasodilator therapy.

The treat-and-repair strategy is recommended over acute vasodilator testing to assess shunt closure, although the level of recommendation is only IIb. Because patients with preexisting PH receiving dual therapy initially achieve PVR reductions of 50% only for a short time,11 interpreting PVR reduction in response to specific PH treatment as assurance that the ASD is closed is considered unclear, particularly when also considering that PH may appear after ASD repair years after closure and has a poor prognosis.12

Post-tricuspid shunts

In posttricuspid shunts, PH is assessed differently and allows higher PH levels for closure. Closure is allowed with PVRs ≥ 5 WU, provided that QP/QS > 1.5 is maintained and assuming that this circumstance will be extraordinarily rare in adults and will be assessed at a facility with experience in managing these patients. In these cases, there is no indication regarding the validity of treat-and-repair or the usefulness of acute vasodilator tests to assess PH reversibility.

The algorithm used to indicate shunt closure begins with LV volume overload, but still does not specify cutoff points or specify a quantification method. This point is particularly controversial in patients with severe PH (PVR > 5 WU), in whom the appearance of LV volume overload is practically impossible because of the logical reduction in left-to-right shunt due to increased pressures. Furthermore, it can lead to inaccurate interpretations because PVR limits that contraindicate closure are not established.
Additionally, the guidelines do not include the PVR to systemic vascular resistance quotient, which is a critical point when assessing shunt closure in pediatric patients.

Ductus closure is now indicated only on the basis of hemodynamic criteria, and the indication due to auscultation of a continuous murmur has been removed.

**LEFT-SIDED OBSTRUCTIVE HEART LESIONS AND AORTOPATHIES**

Updates to the guidelines can be summarized as the need to individualize the recommendations according to the type of aortopathy or obstruction location, the lower thresholds for indicating surgery, the importance of invasive diagnosis, and the preference for percutaneous techniques and valve repair as the first option. In addition, heritable aortic diseases other than Marfan syndrome are included for the first time.

**Valvular, subvalvular, and supravalvular aortic stenosis**

The new indications for aortic stenosis are consistent with the 2017 guidelines on valve disease, the mean gradient for indicating surgery has been lowered to 40 mmHg, and a class I indication has been established for low-flow/low-gradient stenosis in symptomatic patients with ventricular dysfunction and evidence of contractile reserve. Indicators of poor prognosis, such as PH or biomarker elevation, have also been included as a class IIa indication in asymptomatic patients at low surgical risk. Echocardiographic screening is now recommended for first-degree relatives of patients with bicuspid valve (BAV), particularly in people at greater risk for aortic complications (boys, athletes, and if hypertension is present).

In general, the threshold for indicating surgery in asymptomatic patients at low surgical risk in subvalvular and supravalvular aortic stenosis is lower than in valvular stenosis, particularly when it is possible to spare the valve and thus avoid exposing young patients to the cumulative risk of valve replacement-related complications. Potentially of greater interest are updates on the diagnostic approach to both lesions: a recommendation is included on assessment and genetic counseling using microarray techniques if Williams-Beuren syndrome is suspected, and elastin gene sequencing in nonsyndromic presentations of aortic supravalvular stenosis; multimodal imaging is suggested for some forms of subvalvular stenosis and, more importantly, the usefulness of invasive diagnosis is emphasized, particularly for more complex anatomic lesions. Unlike acquired lesions, which are simple and localized, congenital lesions are generally multiple, of tubular morphology, with eccentric jets, and often associated with significant aortic regurgitation or shunts. Because of these features, the modified Bernoulli equation (with velocity near stenosis) should be used to calculate the gradient, and several echocardiographic planes should be used to determine accurate maximal velocities, which means the Doppler-derived gradient accuracy is limited.

**Aortic coarctation and heritable thoracic aortic disease**

In aortic coarctation, it is recommended that the gradient be confirmed by an invasive study, with a preferential indication of percutaneous treatment over surgery, with even less stringent
right-sided obstructive heart lesions and tetralogy of fallot

Right ventricular outflow tract obstruction

In general, the indications for surgery are stricter if pulmonary valve replacement is required, and a useful flow chart is included to assist in decision-making. Percutaneous balloon valvuloplasty is the treatment of choice in cases of nondysplastic pulmonary stenosis, without hypoplastic annulus and with no need for surgery for another cause. It is worth remembering that pulmonary artery aneurysms, at low risk of rupture, do not usually require surgery.

Tetralogy of Fallot

In patients with asymptomatic severe pulmonary regurgitation, cutoffs are established for progressive RV as an indication of valve replacement. Normalization of RV volumes after pulmonary valve replacement is unlikely if they exceed 80 mL/m² for end-systolic volume or 160 mL/m² for end-diastolic volume, although clinical benefit has not yet been shown with this improvement in RV remodeling.

One of the most noteworthy innovations is that percutaneous pulmonary valve implantation has become the treatment of choice, if technically feasible, for patients who already have a bioprosthesis or impaired ducts, currently with a class I recommendation. The reason for this indication (with a more robust recommendation level than for aortic valves in the guidelines for valve disease) is the attempt to minimize the number of reinterventions among the target population, usually with 1 or more prior surgeries. Accordingly, the risk of infective endocarditis should be taken into account when considering the expansion of the indications for percutaneous pulmonary valve replacement.

In the case of a class IIa recommendation (IIb in the previous guidelines), an electrophysiological study (programmed electric pacing) is recommended in patients meeting the risk criteria for SCD, in order to establish the indication for ICD implantation for primary prevention. However, the number of risk criteria to be taken into account (for performance of the study and for the ICD indication) is not specified, nor is ablation indicated for these inducible ventricular tachycardias (VT). Nevertheless, when patients with clinical VT require surgical or percutaneous pulmonary valve implantation, it is recommended (class IIa) that they undergo a preoperative electrophysiological study and ablation of isthmuses that could be less accessible after implantation. The benefit of systematic ablation of slow conduction isthmuses before pulmonary valve replacement is still being researched.

TRANSPOSITION OF THE GREAT ARTERIES

Atrial switch

Although there are no new indications, the class of recommendation has been lowered for the repair or replacement of systemic tricuspid valve with severe regurgitation in symptomatic patients, specifying that the intervention should be performed without relevant ventricular dysfunction (RVEF ≥ 40%), regardless of symptoms (class IIa).

More arrhythmic events, particularly supraventricular, appear with age and affect both quality of life and survival. Catheter ablation is recommended for isthmus-dependent flutter by transbaffle puncture, and programmed electric pacing is mentioned as not being useful for risk stratification, although no evidence has been published to support this statement.

Arterial switch

The usefulness of magnetic resonance imaging (MRI) is highlighted as useful to assess the anatomy of the pulmonary trunk and its branches and to analyze perfusion distribution, without requiring additional nuclear techniques. Reduced pulmonary perfusion is one of the indications for percutaneous treatment of pulmonary branch stenosis, and stenting is confirmed as preferable over surgery.

Potential coronary involvement is deemed relatively unimportant, due to its scant prevalence among adults, and routine screening with imaging techniques is even questioned, emphasizing that surgery on the neoaoortic root should be considered when the diameter is > 55 mm.

Congenitally corrected transposition of the great arteries

The indication for double switch in adulthood is definitively removed due to its high surgical risk. The level of recommendation (class I) for tricuspid valve replacement is increased for symptomatic patients provided systemic RVEF > 40%. Conversely, asymptomatic patients must also have progressive dilation or mild RV dysfunction, and systemic RVEF should be > 40% (class IIa).

There is no recommendation for pharmacologic treatment of asymptomatic patients to improve the prognosis. Additionally, the viability of device-based ventricular assist is discussed, and RV trabeculectomy may be required for proper cannula function.

UNIVENTRICULAR HEART AND FONTAN CIRCULATION

Univentricular heart

Palliative interventions in these patients should always be restricted to highly selected cases and after a careful assessment. The updated guidelines include the recommendation (although class IIb) to create a systemic-pulmonary shunt as potential treatment for patients with severe cyanosis and diminished pulmonary flow not eligible for a Glenn-type connection.

Fontan

Imaging tests are emphasized, whether MRI or computed tomography (CT) for anatomic and functional assessment of collaterals, thrombi, and flow through the cavopulmonary connection, and the importance of the hepatic study is discussed in terms of liver function and screening for advanced stages of
cirsitis and hepatocellular carcinoma. Periodic study is recom-
mended with imaging tests, sonography, and MRI/CT on the liver
plus lab work, including alpha-fetoprotein testing, with a baseline
assessment and regular follow-up based on each patient’s
situation.

The possibility of pulmonary vasodilator treatment is consid-
ered for patients with elevated pulmonary/resistance, provided
that single-ventricle end-diastolic pressure is not elevated (class
IIb), although its usefulness has only been shown in cases with
decreased functional capacity.

Because loss of sinus rhythm and atrial arrhythmias can lead to
severe hemodynamic decline, the role of early electrical cardio-
version is enhanced, and catheter ablation is proposed as the first
therapeutic option.

In the new version, the threshold has been lowered for cardiac
catheterization in the case of clinical complications, but the
procedure is not considered a routine diagnostic test for stable
patients to allow a more accurate anatomic and hemodynamic
assessment than with other techniques. The

The indication of anticoagulant therapy is still a controversial
issue, although the same recommendations are established: atrial
thrombi, arrhythmias, or thromboembolic events. Direct-acting
anticoagulants are a possible option, with safety and efficacy based
only on registry data, with no randomized studies to support them.

Protein-losing enteropathy may be treated by transplantation
when medical treatment fails, but no criteria are established for
heart or liver transplant in Fontan.

CORONARY ANOMALIES

Anomalous aortic origin of a coronary artery

Anomalous aortic origin of the right coronary artery (AAORCA)
from the left aortic sinus is 6- to 10-fold more common than
anomalous origin of the left coronary artery (AAOLCA) from the
right aortic sinus, but the higher risk is associated with the latter as
a cause of SCD in individuals younger than age 35 years who
practice strenuous physical exercise. Diagnosis requires assessing
anatomic and clinical aspects and proving inducible ischemia with
imaging techniques based on nonpharmacologic stress, although
the sensitivity of these techniques is low, particularly in AAORCA.
CT is the technique of choice, as it provides more information than
invasive coronary angiography.

Surgical indications are controversial for several reasons: the
prognostic value of the various anatomic and clinical risk factors,
the high variability of the surgical techniques described, with no
evidence on the prevention of SCD for each one, and the persistence
of ischemia or symptoms in some patients after surgery. These
considerations must be taken into consideration, along with
surgical experience to interpret the indications of the guidelines.
Surgery is considered reasonable for patients with AAORCA or
AAOLCA and demonstrable ischemia regardless of clinical symp-
toms and for patients with asymptomatic AAOLCA and no
ischemia, but with risk anatomy (class Ila). It is not considered
indicated for asymptomatic patients with AAORCA without
ischemia or risk anatomy (class III), and there is no evidence for
drug therapy, exercise restrictions, or arrhythmia studies.

Anomalous coronary artery from the pulmonary artery

Patients with an abnormal coronary artery from the pulmonary
artery have elevated mortality in childhood, but can survive to
adulthood by developing intercoronary collateral circulation. The
clinical course varies from silent forms to HF, arrhythmias, etc. The
anomalous origin may be from either coronary artery: left (ALCAPA)
or right (ARCAPA), which has fewer repercussions. ALCAPA cases are always surgical, whereas in ARCAPA, surgery is
reserved for symptomatic cases with ventricular dysfunction or
demonstrable ischemia.

CONCLUSIONS

The cardiologic care of adults with CHD should focus on
multidisciplinary care in specialized units that can offer clinical
experience and all the diagnostic and therapeutic techniques
required by this complex, heterogeneous population. These
guidelines lay down recommendations based on currently
available evidence, but there are still considerable gaps in the
knowledge of these diseases that we hope to clarify in upcoming
times through multicenter network research and the use of new
methodologies (artificial intelligence).

CONFLICTS OF INTEREST

The authors declare no conflicts related to this article.

APPENDIX. AUTHORS

SEC Working Group for the ESC 2020 Guidelines for the
management of adult congenital heart disease: Laura Dos
(coordinator), Joaquín Rueda Soriano (coordinator), Pablo Ávila,
Pilar Escribano, M. Elvira Garrido-Lestache Rodríguez-Monte, Ana
Elvira González, Isaac Martínez Bendayan, Silvia Montserrat,
Pastora Gallego, Rafael Alonso, and M. Antonia Martínez Mombián.

Expert reviewers for the ESC 2020 for the management
of adult congenital heart disease: Rocío García Orta, José María
Oliver Ruiz, Rafael Peinado Peinado, Óscar Cano Pérez, Federico
Gutiérrez Larraya, Ariana González, Irene Méndez, and María Lázaro Salvador.

SEC Guidelines Committee: Pablo Avanzas, Gemma Berga
Congost, Araceli Boraita, Héctor Bueno, David Calvo, Raquel
Campuzano, Victoria Delgado, Laura Dos, Ignacio Ferreirea-Gonzá-
lez, Juan José Gómez Doblas, Domingo Pascual Figal, Antonia
Sambola Ayala, Ana Viana Tejedor, José Luis Ferreiro (copresident),
and Fernando Alfonso (copresident).

REFERENCES

10.1093/eurheartj/ehaa554.
2011;64:795–796.
3. Baumgartner H, Bonhoeffer P, De Groot NM, et al. ESC Guidelines for the manage-
ment of grown-up congenital heart disease (new version 2010). Eur Heart J.
2010;31:2915–2957.
in Spain: health care structure and activity, and clinical characteristics. Rev Esp
5. De Torres-Alba F. Adult congenital heart disease in Spain: present situation and
care for adults with congenital heart disease and for training in the subspecialty
of ‘Grown-up Congenital Heart Disease’ in Europe: a position paper of the Working
Group on Grown-up Congenital Heart Disease of the European Society of
congenital heart disease: a position paper of the Working Group of Grown-Up
Congenital Heart Disease and the Heart Failure Association of the European Society